| Project/Area Number |
20591852
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
KONAKA Hiroyuki Kanazawa University, 附属病院, 講師 (40334768)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MIZOKAMI Atsushi 金沢大学, 附属病院, 講師 (50248580)
KYO Satoru 金沢大学, 医学系, 講師 (50272969)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2008: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 前立腺癌 / エストロゲン受容体 / シグナル伝達 / 遺伝子治療 / SCIDマウス / エストロゲン / ER / リガンド / 転写活性 / NF-κB / AR / ERE / シグナル伝達系 |
|---|
| Research Abstract |
To reconsider a significance of Estrogen-based therapy in hormone refractory prostate cancer and elucidate a comprehensive mechanisms through which two type of Estrogen receptor, ERα and ERβ,can differently mediate signal transduction pathways. Consequently, our study made it clear that ERα might act as a pedal but ERβ as a brake in progression of prostate cancer, and also suggested the possibility of molecular targeting therapy for ERβ and gene therapy using ERβ expression vector and its ligand Estradiol.
|
